RadNet (RDNT) has drawn fresh attention after forming a joint venture with Saint Alphonsus Health System in Idaho, acquiring a majority stake in Intermountain Medical Imaging and preparing to report upcoming first quarter earnings.

Despite the Idaho joint venture and ongoing focus on AI-enabled imaging, RadNet’s share price return has been weak year to date, with a 19% decline and a 17% 3 month pullback, even as the 1 year total shareholder return is slightly positive and the 3 and 5 year total shareholder returns remain strong.

If this mix of healthcare and AI has your attention, it could be a good moment to broaden your watchlist with 35 healthcare AI stocks

So with RadNet’s shares pulling back despite AI-focused growth efforts and the Idaho expansion, is the stock trading at a discount to its fundamentals, or is the market already pricing in much of its future potential?

Most Popular Narrative: 36% Undervalued

RadNet's most followed narrative pegs fair value at $89.88 a share versus the recent $57.50 close, framing the current pullback as a sizable valuation gap built on detailed earnings and cash flow expectations.

Ongoing investments in AI-powered imaging solutions (e.g., DeepHealth, See-Mode, iCAD) are materially increasing center throughput, boosting capacity utilization, and driving more high-margin advanced procedures, directly enhancing both revenue growth and EBITDA margins as adoption scales through 2026.

Curious what kind of revenue run rate, margin path, and future earnings multiple are baked into that $89.88 figure? The narrative leans on ambitious growth, a step change in profitability and a premium valuation usually reserved for higher growth sectors, all tied to specific forecasts across several years.

Result: Fair Value of $89.88 (UNDERVALUED)

However, the story only holds if imaging demand, reimbursement and AI rollouts keep pace, and if ongoing acquisitions and platform integrations avoid cost overruns or delays.

Another View: Revenue Multiple Flags Rich Pricing

The consensus narrative leans on future earnings and cash flows, but the current P/S ratio of 2.2x tells a different story. It sits well above the US Healthcare industry at 1.2x and the 0.9x fair ratio, even though it is below the peer average of 2.7x. This raises a simple question: is the discount really as large as it looks?

Next Steps

Sentiment looks mixed here, with both optimism and caution in play. Consider moving quickly, reviewing the numbers for yourself, and weighing the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If RadNet is on your radar, do not stop there. Broadening your watchlist with other focused stock ideas can help you spot opportunities you might otherwise miss.

• Target resilient returns first by using the 71 resilient stocks with low risk scores to focus on companies with lower overall risk profiles.
• Hunt for quality at a sensible price with the 51 high quality undervalued stocks and see which stocks currently trade below their assessed worth.
• Spot potential future standouts early through the screener containing 23 high quality undiscovered gems and keep an eye on companies that are not yet widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.